Skip to content
    ANNX
    Earnings call· Jun 2026(Q2 FY26)

    Annexon Q2 FY26 earnings call ANNX

    Aug 12, 2026 Source

    Executive summary

    Annexon Q2 FY26 — ARCHER II Program Expanded, GBS BLA on Track

    Annexon is advancing its lead programs, tanruprubart for GBS and vonaprument for geographic atrophy, towards regulatory milestones. The GBS program is on track for a Q4 FY26 US BLA submission, supported by compelling FORWARD study data. The GA program's ARCHER II Phase III trial was strategically expanded to include a Month 24 dual primary endpoint, aiming to strengthen the long-term profile and increase overall program success, while maintaining confidence in the Q4 FY26 Month 15 readout. The company also bolstered its financial position with a new credit facility, extending its cash runway into 2028.

    Highlights

    5
    • Tanruprubart (GBS) under regulatory review in Europe and on track for US BLA submission in Q4 FY26, with FORWARD study showing rapid improvement in all 10 treated patients.

    • Vonaprument (GA) ARCHER II Phase III trial expanded to include a Month 24 dual primary endpoint, strengthening the program and potential franchise.

    • Initiation of ARCHER II open-label extension (OLE) study, allowing all patients to receive vonaprument after Month 24.

    • Secured a credit facility with Oxford Finance for up to $200M, extending cash runway into 2028.

    • Strong trial execution for ARCHER II with patient discontinuation rate less than 10% and dosing compliance over 95%, exceeding targets.

    Concerns

    2
    • The decision to add a Month 24 primary endpoint for ARCHER II implies a split of alpha between Month 15 and Month 24, potentially tightening the statistical threshold for the Month 15 readout.

    • The company did not disclose the specific alpha split or the current powering for Month 15 and Month 24, leading to analyst questions about confidence in the Month 15 endpoint.

    Guidance & targets

    5
    CategoryTargetConfidence
    Tanruprubart (GBS) US BLA Submission
    On track to submit
    high materiality
    High
    Vonaprument (GA) ARCHER II Month 15 Primary Endpoint Readout
    Expected in the fourth quarter of this year
    high materiality
    High
    Vonaprument (GA) ARCHER II Substudy Analysis
    Results expected in the first quarter of 2027
    medium materiality
    Medium
    Vonaprument (GA) ARCHER II Month 24 Analysis Completion
    Expected to be completed in the third quarter of 2027
    high materiality
    High
    Cash Runway
    Into 2028
    high materiality
    High

    Operational metrics

    14
    Credit Facility Access
    $200M
    Q2 FY26

    Entered a credit facility to strengthen financial position and diversify capital structure.

    Cash Runway
    Into 2028
    Q2 FY26

    Extended due to the new credit facility.

    ARCHER II Patient Discontinuation Rate
    <10%lower than anticipated
    YTD

    Exceeded targets, contributing to increased statistical power.

    ARCHER II Dosing Compliance
    >95%exceeded targets
    YTD

    Exceeded targets, contributing to increased statistical power.

    ARCHER II Patient Enrollment
    65930 more than original target
    Trial completion

    Slightly enhanced powering due to brisk enrollment.

    GBS Patients Diagnosed Annually
    150,000worldwide
    Annual

    Represents the target patient population for tanruprubart.

    GBS Patients
    22,000across US and Europe
    Annual

    Number of patients afflicted each year.

    GBS Annual Healthcare Burden
    >$20Bin the US alone
    Annual

    Estimated healthcare cost associated with GBS.

    GBS 1-Year Mortality Rate
    10%overall
    1-year

    Despite treatment, mortality remains high, especially for older patients.

    GA Patients
    8Mworldwide
    Current

    Total patient population for vonaprument.

    GA Patients
    1.5Min the US alone
    Current

    US patient population for vonaprument.

    ARCHER II Statistical Power
    >90%
    Overall study

    The overall study is highly powered for both time points.

    RPE Growth Protection
    10%
    Second 6 months

    Observed in the second 6 months of the ARCHER I study, indicating healthier neuronal unit.

    ARCHER II Masked Event Accruals
    On trackin line with projections
    YTD

    Continues to track over several months, giving confidence in ARCHER II.

    Industry KPIs

    4
    MetricValueDetails
    Pipeline read out calendarMultiple
    Regulatory approvals filingsMultiple
    Peak long term sales guidance$100B+USD
    Clinical trial efficacy safety dataRapid, clinically meaningful improvement

    Deals & partnerships

    1
    Oxford FinanceCredit facility providing non-dilutive capitalUp to $200M

    Provides access to non-dilutive capital to strengthen financial position and support growth strategies.

    Risks & headwinds

    2
    ARCHER II Month 15 primary endpoint not metQ4 FY26

    Potential for DMC to recommend study continue to Month 24 analysis instead of declaring positive at Month 15.

    Mitigation: Strategic addition of Month 24 dual primary endpoint to increase overall program success probability; strong trial execution (low discontinuation, high compliance, over-enrollment) provides increased statistical power for both time points.

    Statistical threshold for Month 15 endpoint tightened due to alpha splitOngoing

    Alpha is being split between Month 15 and Month 24.

    Mitigation: Management states that due to strong trial execution, the reduction in likelihood for a Month 15 win is negligible, and the study remains well-powered at both time points.

    What to watch in Q3 FY26

    4

    Tanruprubart US BLA Submission

    Q4 FY26
    CurrentOn track for Q4 FY26 submission
    TargetSubmission completed

    Why it matters

    Successful submission is a key regulatory milestone for commercialization of the GBS program in the US.

    Tanruprubart is now under regulatory review in Europe, and we are on track to submit the U.S. BLA in the fourth quarter of this year.

    Q&A highlights

    6

    Has the dual primary endpoint strategy for ARCHER II been shared with regulators (US and global), and what feedback was received?

    Regulators (both US and EU) have confirmed that if Annexon wants to include Month 24 efficacy data in the label, alpha would need to be applied to Month 24. This was already part of the study design for safety, but now includes efficacy.

    Yes, the short answer is, yes, both regulators on both sides of the pond have been very clear that if we want to include month 24 in the label, we would need to apply alpha to month 24.

    asked by Anupam Rama · answered by Douglas Love

    2 min read5 chapters

    Detailed Narrative

    01

    GBS Program Update and Regulatory Path

    Annexon provided an update on its GBS program with tanruprubart, highlighting it as the first positive placebo-controlled pivotal data in 110 years. The drug is under regulatory review in Europe, and the company plans to submit the U.S. BLA in Q4 FY26. Initial results from the FORWARD study's first cohort of 10 patients showed rapid, clinically meaningful improvement in loss of strength within 4 days, with 4 bed-bound patients regaining ability to walk. The data also showed outsized improvements in severely affected patients, including one weaned from mechanical ventilation within 4 days. These findings are consistent with Phase III results where 90% of patients responded by week 1, supporting a broad treatment label.

    02

    GA Program Expansion and Rationale

    The ARCHER II Phase III trial for vonaprument in geographic atrophy (GA) was strategically expanded to include an independent Month 24 dual primary endpoint alongside the existing Month 15 primary endpoint. This decision was driven by strong trial execution, including over-enrollment by 30 patients, a patient discontinuation rate below 10%, and dosing compliance over 95%. Management stated the expansion strengthens the program, builds a 'moat' around the franchise, and provides additional time to demonstrate the growing treatment effect observed in proof-of-concept data, without weakening confidence in the Month 15 readout.

    03

    Vision Preservation vs. Lesion Growth in GA

    Management emphasized that the primary goal for vonaprument in GA is vision preservation, not solely lesion growth reduction. They noted that while lesion growth is a current focus in the community, it has not correlated with vision preservation in previously approved therapies. Annexon's focus is on protecting photoreceptor cells and neuronal units, as measured by ellipsoid zone, which they believe is a more critical biomarker for neurodegenerative disease. They anticipate seeing protection of RPE lesion at later time points based on Phase II data, but prioritize vision outcomes.

    04

    Financial Strengthening and Capital Structure

    Annexon strengthened its financial position by securing a credit facility with Oxford Finance, providing access to up to $200 million in non-dilutive capital. This facility extends the company's cash runway into 2028, enhancing financial and operational flexibility as it prepares for global commercialization of its programs. The move also diversifies the capital structure and supports both near- and longer-term growth strategies.

    05

    Regulatory Designations and Support for Vonaprument

    Vonaprument has received Fast Track designation from the FDA and PRIME designation from the EMA, making it the only geographic atrophy program with this status from the EMA. It has also been selected for the EMA's product development coordinator pilot, which offers enhanced regulatory support, including expedited scientific advice and MAA submission readiness. These designations facilitate more frequent engagement with regulators, supporting the program's path towards potential registration.

    AI-generated summary of the company’s earnings call. Not investment advice.